Integrating New PAH Therapies into Clinical Practice

Video content above is prompted by the following questions:

• Sotatercept, a new treatment for PAH, recently received FDA approval in April 2024. How do you see this new therapy, as well as other emerging pulmonary arterial hypertension (PAH) treatments, fitting into the current treatment paradigm for PAH?
• What key factors should guide clinicians in determining the appropriate use of these new therapies in clinical practice?